...
首页> 外文期刊>Oncogene >HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
【24h】

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

机译:恶性细胞中HLA抗原的变化:表观遗传机制和生物学意义

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Changes in classical and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesions. These changes, which are described in this review are believed to play a major role in the clinical course of the disease since both HLA class I and class II antigens are critical to the interaction between tumor cells and components of both innate and adaptive immune system. Abnormalities in HLA antigen expression in malignant cells, which range in frequency from 0–90%, are caused by distinct mechanisms. They include defects in β2-microglobulin (β2m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, defects in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or more of the antigen processing, machinery (APM) components. More recently, epigenetic events associated with tumor development and progression have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and tumor antigen (TA) expression in malignant cells. The types of epigenetic modifications that may occur in normal and malignant cells as well as their role in changes in HLA antigen expression by malignant cells have been reviewed. The epigenetic events associated with alterations in HLA antigen expression may be clinically relevant as, in some cases, they have been shown to impair the recognition of tumor cells by components of the adaptive immune system. The functional relevance and potential clinical significance of these epigenetic alterations have been addressed. Finally, unlike genetic alterations, epigenetic modifications can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. Therefore, strategies to overcome epigenetic modifications underlying changes in HLA antigen expression in malignant cells have been discussed.
机译:已在恶性病变中鉴定出经典和非经典HLA I类以及HLA II类抗原的变化。据信,本综述中描述的这些变化在疾病的临床过程中起着重要作用,因为HLA I类和II类抗原都对肿瘤细胞与先天性和适应性免疫系统的组成部分之间的相互作用至关重要。恶性细胞中HLA抗原表达异常的频率范围为0-90%,是由不同的机制引起的。它们包括β2-微球蛋白(β2m)合成中的缺陷,编码HLA抗原重链的基因缺失,抑制HLA抗原重链转录或翻译的突变,控制HLA抗原的调节机制中的缺陷。一种或多种抗原加工机械(APM)组件中的表达和/或异常。最近,已发现与肿瘤发生和发展相关的表观遗传事件是恶性细胞中HLA抗原,APM成分,共刺激分子和肿瘤抗原(TA)表达变化的基础。审查了可能在正常和恶性细胞中发生的表观遗传修饰的类型,以及它们在恶性细胞改变HLA抗原表达中的作用。与HLA抗原表达改变相关的表观遗传事件可能与临床相关,因为在某些情况下,已证明它们会削弱适应性免疫系统的组成部分对肿瘤细胞的识别。这些表观遗传改变的功能相关性和潜在的临床意义已得到解决。最后,与遗传改变不同,在某些情况下,表观遗传修饰可以通过诱导DNA低甲基化或抑制组蛋白去乙酰化的药物逆转。因此,已经讨论了克服在恶性细胞中HLA抗原表达变化基础的表观遗传修饰的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号